A Phase Ib Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) in Previously Treated Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)

Conditions:   Gastric Cancer;   Esophageal Adenocarcinoma;   Hepatocellular Carcinoma;   Colorectal Cancer
Interventions:   Drug: Cabozantinib;   Drug: Durvalumab
Sponsors:   Anwaar Saeed;   AstraZeneca;   Exelixis
Not yet recruiting

https://ift.tt/2Je5tSn